GamaMabs raises EUR 15M in series B

GamaMabs Pharma S.A. (Tolouse, France) raised EUR 15 million ($16.4 million) in a series B round led by new investor Edmond de Rothschild Investment Partners (EdRIP) via its BioDiscovery 4 fund. Existing investors InnoBio, Irdinov, Aldo Invest, and iXO Private Equity also participated.

GamaMabs' lead candidate GM102 ( 3C23K) is a humanized mAb against anti-Mullerian hormone receptor type II (AMHR2). The company expects to begin a Phase I study in 1H16 to treat AMHR2-positive gynecological cancers, with data due in 1H17. ...